Condition: Advanced Solid Tumor · Non Small Cell Lung Cancer · Untreated Advanced NSCLC · Sponsor: Synthekine
This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.
This description comes directly from the study's public registry record.
Synthekine STK-012-101 Contact · 650-606-6319 · STK-012-101.contact@synthekine.com
Always discuss trial participation with your own doctor first.
| University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| Beverly Hills Cancer Center | Beverly Hills, California, United States | Recruiting |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Active Not Recruiting |
| Cedars Sinai | Los Angeles, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica, California, United States | Recruiting |
| Yale New Haven Hospital, Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Georgetown University | Washington D.C., District of Columbia, United States | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| University of Maryland | Baltimore, Maryland, United States | Recruiting |
+ 35 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05098132